The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
Dr Kirollos Hanna Details How His Practice Chooses Which Biosimilars to Add to Its FormularyOctober 16th 2021
Kirollos Hanna, PharmD, manager of Oncology Pharmacy at the University of Minnesota Medical Center, explains the process behind how his practice chooses which biosimilars to stock and provide for patients.
Reference, Biosimilar Pegfilgrastim Can Be Safely Administered Same Day as ChemotherapyOctober 12th 2021
Investigators concluded that reference or biosimilar pegfilgrastim could be safely administered to patients with lymphoma on the same day they receive chemotherapy, which could reduce scheduling burden and risk of COVID-19 exposure.
Despite Awareness of Biosimilars, More Education Among Oncologists in Brazil NeededOctober 6th 2021
Brazilian oncologists showed a solid knowledge base about biosimilars and their safety; however, concerns over extrapolation and interchangeability requirements remained, suggesting that more education on these subjects is needed.
Dr Kashyap Patel: Misleading Reference Product Advertising and the Damage to Biosimlars' ReputationOctober 2nd 2021
Regulatory agencies have already begun calling companies out for misdirecting the public about the safety and efficacy of reference products in comparison to biosimilars, and it's important to continue to do so, said Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates.
Bevacizumab Biosimilar Found to Have Safety, Efficacy Equivalent to Reference Avastin for NSCLCOctober 1st 2021
Bevacizumab biosimilar LY01008 demonstrated comparative safety, efficacy, immunogenicity, and pharmacokinetic profiles to the reference product Avastin when combined with paclitaxel and carboplatin in patients with non–small cell lung cancer (NSCLC).
Dr Kashyap Patel: How COVID-19 Is Expected to Influence Usage of Biosimilar PegfilgrastimsSeptember 24th 2021
The emergence of new COVID-19 variants and the lower-than-anticipated vaccination rates could lead to a greater use of pegfilgratim biosimilars in cancer settings, explained Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates.
Dr Kashyap Patel: The Pros and Cons of Pegfilgrastim Biosimilars vs Neulasta OnproSeptember 17th 2021
Cost and lack of insurance are big drivers of why a physician may choose to prescribe a pegfilgrastim biosimilar over the convenient on-body device for the originator, said Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates.
Samsung Bioepis Releases Positive 5-Year Follow-up Results for Trastuzumab BiosimilarSeptember 15th 2021
Samsung Bioepis found during a 5-year follow-up study that Ontruzant, the company’s trastuzumab biosimilar, had comparable cardiac safety and long-term efficacy with the reference product Herceptin.
Dr Kashyap Patel Highlights How the Pandemic Influenced Utilization of Pegfilgrastim BiosimilarsSeptember 10th 2021
Reducing the risks of secondary neutropenia, exposure to COVID-19, mortality, and financial toxicity were all major reasons the use of pegfilgrastim biosimilar gained traction during the pandemic, said Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care.
Sandoz, Bio-Thera Solutions Enter Deal to Commercialize Avastin BiosimilarSeptember 10th 2021
Bio-Thera Solutions and Sandoz have partnered for to allow for the commercialization of BAT1706, a bevacizumab biosimilar referencing Avastin, for the treatment of several forms of cancer.
Saudi Researchers Call for Greater Use of Trastuzumab Biosimilars to Offset Breast Cancer CostsSeptember 2nd 2021
Switching from Herceptin (reference trastuzumab) to trastuzumab biosimilars could significantly reduce direct medication costs attributed to breast cancer management in Saudi Arabia, researchers concluded.
Dr Neal Dave: Are Physicians Excited for More Biosimilars to Enter the Oncology Space?August 27th 2021
Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, talks about the anticipation for more biosimilars to enter the oncology market and the current level of interest in the pipeline.
Study Confirms Overall Survival in DLBCL Is Comparable Between Rituximab Biosimilars and RituxanAugust 24th 2021
In comparison with reference rituximab (Rituxan), the use of rituximab biosimilars in combination therapy produced similar 3-year overall survival among patients with large-B-cell lymphoma (DLBCL), investigators concluded.
Site of Care Potentially Limits Cost Savings From Biosimilars
Although previous work has found lower costs for biosimilar filgrastim compared with reference filgrastim, this study found that site of care can change this calculus, reducing savings.
Dr Neal Dave Explains Why Biosimilars Should Be Favored Over Reference ProductsAugust 20th 2021
Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, discusses the potential for biosimilar utilization to grow and the reasons why his practice favors them over reference products.
Switching to a Pegfilgrastim Biosimilar May Facilitate Access to ChemotherapyAugust 19th 2021
Switching patients from reference pegfilgrastim to a biosimilar could lead to substantial cost savings, with potential to offset the cost of and allow for greater access to chemotherapy treatment, investigators concluded.
2020 Spend and Trend Report Shows Biosimilar Competition Led to Decreases in Originator Prices, ClaimsAugust 12th 2021
A 2020 trends report from Artemetrx showed how biosimilar competition has contributed to lower average sales prices and claim percentages for originator products, suggesting that biosimilars are making a difference despite slow uptake.
Neal Dave, PharmD, Discusses the Importance of Consistently Reevaluating the Cost-Effectiveness of BiosimilarsAugust 6th 2021
Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, talks about the importance of conducting regular evaluations to ensure that prescribing the most cost-effective option, whether that be a biosimilar or the reference product.
Real-world Evidence Shows Good Acceptance of Rituximab Biosimilar for NHL, CLLAugust 5th 2021
In one of the first studies to examine real-world evidence on rituximab biosimilars in the United States, investigators found that many providers treating patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are regularly prescribing a biosimilar rituximab.
Alliance for Patient Access Releases Paper on Biosimilar Best Practices in OncologyJuly 26th 2021
Two oncologists dive into the reasons behind physician hesitancy and unwillingness to prescribe biosimilars to patients with cancer and make suggestions on how to increase confidence in these agents.
Originator Drugs Experience Price Drops When Multiple Biosimilars Are Added to Reimbursement ListsJuly 15th 2021
The price of reference products reduced each time a new biosimilar was added to a drug program’s reimbursement list, supporting the notion that reimbursing biosimilars creates more competition and lowers drug costs, according to a Polish study.
Patient Advocacy Organizations Join Forces to Endorse BIOSIM ActJuly 7th 2021
Twenty-eight patient advocacy groups wrote a letter pledging endorsement of the Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act, a bill aimed at increasing reimbursement and incentivizing prescriptions for biosimilars.